Drug Detail:Tafenoquine (krintafel) (monograph) (Krintafel)
Drug Class:
Tafenoquine Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of tafenoquine during breastfeeding. Tafenoquine can cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. If tafenoquine is needed by the mother, testing the mother and infant for G6PD deficiency is required before the drug is given. Because the half-life of tafenoquine averages 15 days, the manufacturer recommends that breastfeeding should not breastfeed for 3 months after the dose if the infant is G6PD deficient.
Drug Levels
Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Primaquine
Substance Identification
Substance Name
Tafenoquine
CAS Registry Number
106635-80-7
Drug Class
-
Breast Feeding
-
Lactation
-
Anti-Infective Agents
-
Antiparasitic Agents
-
Antimalarials
-
Antiprotozoal Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
